Clinical Trials Browser

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

Clinical Trials

ANTARES

Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

MesoPDT

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

BIMES

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

MAGIC-AKI

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

A Study of Sacituzumab Govitecan in People With Mesothelioma

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

NERO

Olaparib in Patients With HRD Malignant Mesothelioma

ACROPOLI

RAMES

Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma

NIPU

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

PrE0505

UNITO-001

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma

VIM

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

MAPS2

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

ATREUS

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

HIPEC/IPHC

18F-FSPG PET/CT for Cancer Patients on Therapy

UAB0901

Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma

Tomotherapy Treatment for Mesothelioma

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

SKOPOS

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

AGILI

SMS

IPHC

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma